Collegium Pharmaceutical (NASDAQ:COLL) Earns Buy Rating from HC Wainwright

Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $50.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 66.39% from the company’s previous close.

Several other equities analysts also recently commented on the stock. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research note on Friday, January 10th. Piper Sandler decreased their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $43.60.

Collegium Pharmaceutical Price Performance

COLL opened at $30.05 on Monday. The stock’s 50-day moving average price is $30.69 and its 200 day moving average price is $32.64. Collegium Pharmaceutical has a 12-month low of $27.28 and a 12-month high of $42.29. The firm has a market cap of $946.15 million, a price-to-earnings ratio of 12.95 and a beta of 0.99. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.09. The business had revenue of $181.95 million for the quarter, compared to analysts’ expectations of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. As a group, sell-side analysts expect that Collegium Pharmaceutical will post 5.62 earnings per share for the current year.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the sale, the executive vice president now owns 119,184 shares of the company’s stock, valued at approximately $3,937,839.36. This trade represents a 18.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Colleen Tupper sold 1,949 shares of the business’s stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00. Following the sale, the chief financial officer now owns 177,195 shares of the company’s stock, valued at $5,315,850. This represents a 1.09 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 109,193 shares of company stock valued at $3,243,594 over the last quarter. 3.98% of the stock is owned by insiders.

Institutional Trading of Collegium Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in COLL. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Collegium Pharmaceutical during the fourth quarter worth approximately $3,489,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Collegium Pharmaceutical by 11.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 66,389 shares of the specialty pharmaceutical company’s stock worth $1,902,000 after acquiring an additional 7,063 shares during the last quarter. Velan Capital Investment Management LP acquired a new position in shares of Collegium Pharmaceutical in the 4th quarter valued at $822,000. Vident Advisory LLC raised its position in Collegium Pharmaceutical by 27.8% in the 4th quarter. Vident Advisory LLC now owns 16,898 shares of the specialty pharmaceutical company’s stock valued at $484,000 after purchasing an additional 3,672 shares during the last quarter. Finally, Virtus Fund Advisers LLC boosted its stake in Collegium Pharmaceutical by 30.5% during the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 565 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.